UBS AM
ARIA

UBS AM’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

UBS AM’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-78,804
Closed -$981K – 2526
2016
Q4 		$981K Sell
78,804
-50,160
-39% -$604K ﹤0.01% 1564
2016
Q3 		$1.77M Sell
128,964
-1,732
-1% -$17.4K ﹤0.01% 1429
2016
Q2 		$965K Hold
130,696
– – ﹤0.01% 1673
2016
Q1 		$836K Sell
130,696
-13,978
-10% -$78.3K ﹤0.01% 1708
2015
Q4 		$904K Buy
144,674
+2,800
+2% +$18.4K ﹤0.01% 1786
2015
Q3 		$829K Buy
141,874
+32,380
+30% +$249K ﹤0.01% 1800
2015
Q2 		$905K Buy
109,494
+10,100
+10% +$89.3K ﹤0.01% 1722
2015
Q1 		$819K Buy
99,394
+3,400
+4% +$25.1K ﹤0.01% 1721
2014
Q4 		$660K Hold
95,994
– – ﹤0.01% 1788
2014
Q3 		$518K Buy
95,994
+17,500
+22% +$102K ﹤0.01% 1864
2014
Q2 		$500K Sell
78,494
-14,660
-16% -$101K ﹤0.01% 1908
2014
Q1 		$751K Buy
93,154
+4,000
+4% +$31.2K ﹤0.01% 1668
2013
Q4 		$608K Sell
89,154
-1,537,884
-95% -$8.3M ﹤0.01% 1718
2013
Q3 		$29.9M Buy
1,627,038
+316,301
+24% +$6.14M 0.04% 483
2013
Q2 		$22.9M Buy
+1,310,737
New +$23.2M 0.03% 530

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

UBS AM's ARIA Position: Q1 2017 in Review

UBS AM sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 78,804 shares — an estimated $981K sold.

UBS AM first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $29.9M in Q3 2013. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • UBS AM reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • UBS AM sold 78,804 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $981K.
  • UBS AM first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
  • UBS AM's Ariad Pharmaceuticals Inc position peaked at $29.9M in Q3 2013.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on UBS AM's 13F filing for Q1 2017, filed 4 May 2017.